profit from every $100 of sales.
$0$100
Lantheus Holdings
$101.60-0.02% today
+90.4% in 1 year
1-year low $52.501-year high $110.94
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $28.45 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Lantheus Holdings sold, what it kept, and what it did with the cash.
Sales went from $935 million in 2022 to $1.54 billion in 2025, with $234 million of profit last year.
SalesProfit
Lantheus Holdings handed back 86% of the cash it generated last year.
Buybacks $300M
Free cash flow 2025$349M
Bought back its own shares$300M
Paid as dividends–
Cash vs. debt$359M vs. $619M
Lantheus Holdings vs. similar companies
Lantheus Holdings grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lantheus Holdings | 28.5× · Fair price | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Lantheus Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 339 | 425 | 935 | 1,296 | 1,534 | 1,542 | |
| 139 | 188 | 582 | 710 | 988 | 942 | |
| -4 | -61 | 36 | 365 | 449 | 316 | |
| 23 | -25 | 82 | 491 | 515 | 404 | |
| -13 | -71 | 28 | 327 | 312 | 234 | |
| -0.25 | -1.06 | 0.40 | 4.65 | 4.36 | 3.41 | |
| 40.9% | 44.1% | 62.2% | 54.7% | 64.4% | 61.1% | |
| -1.2% | -14.3% | 3.9% | 28.1% | 29.2% | 20.5% | |
| -4.0% | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 870 | 864 | 1,321 | 1,651 | 1,980 | 2,227 |
| Cash | 80 | 99 | 416 | 714 | 913 | 359 |
| Total debt | 236 | 191 | 584 | 617 | 619 | 619 |
| Total liabilities | 356 | 399 | 874 | 835 | 892 | 1,138 |
| 514 | 464 | 447 | 816 | 1,088 | 1,090 | |
| 54 | 67 | 71 | 70 | 72 | 68 | |
| -0.2% | -8.1% | 2.6% | 23.8% | 20.9% | 15.4% | |
| -2.6% | -15.3% | 6.3% | 40.0% | 28.7% | 21.4% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 16 | 54 | 282 | 305 | 545 | 390 | |
| – | – | 18 | 47 | 80 | 42 | |
| – | – | 263 | 259 | 465 | 349 | |
| Dividends paid | – | – | – | – | – | – |
| 0 | 0 | 75 | 0 | 100 | 300 | |
| 14 | 16 | 29 | 51 | 76 | 86 |
Valuation
- 28.5×
- 19.7×
- –
- 5.3×
- 4.3×
- 19.1×
- 17.1×
- 5.2%
- 3.5%
- 0.0%
Profitability
- 61.1%
- 20.5%
- 15.2%
- 23.9%
- 10.8%
- 10.9%
- 24.3%
- 11.9%
- 14.4%
- 11.7%
Growth
- +35.3%
- –
- −28.2%
- –
- +0.0%
Financial health
- 0.6×
- 0.00
- 0.0%
- 14.6×
- 2.83
- 2.64
- 0.66
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 25%of 958
Top 22%of 889
Bottom 46%of 601
Top 15%of 890
Top 22%of 987
What analysts expect
- Average price target
- $101.00
- Range
- $95.00 – $110.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 1.46 | 1.25 | +16.8% |
| Feb 26, 2026 | 1.67 | 1.18 | +41.5% |
| Nov 6, 2025 | 1.27 | 1.27 | +0.0% |
| Aug 6, 2025 | 1.57 | 1.64 | −4.3% |
| May 7, 2025 | 1.53 | 1.68 | −8.9% |
| Feb 26, 2025 | 1.59 | 1.58 | +0.6% |
| Nov 6, 2024 | 1.70 | 1.56 | +9.0% |
| Jul 31, 2024 | 1.80 | 1.83 | −1.6% |
News
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’sSeeking Alpha · Aug 14, 2026The newest story we have is from Aug 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
39No pass
Philip Fisher
69Pass
Peter Lynch
94Pass
Joel Greenblatt
25No pass
Charlie Munger
59No pass
Terry Smith
59No pass
Questions about Lantheus Holdings
Is Lantheus Holdings a good stock to buy?
A solid business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lantheus Holdings AI analysis
What does Lantheus Holdings do?
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It is in Drug Manufacturers - Specialty & Generic, based in Bedford, MA, United States, with 1,193 employees.
Does Lantheus Holdings pay a dividend?
No. Lantheus Holdings does not pay a dividend at the moment; in 2025 it returned $300 million to shareholders by buying back its own shares.
Is Lantheus Holdings stock halal?
Yes. Lantheus Holdings passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has Lantheus Holdings stock done over the past year?
Up 90.4% over the past twelve months, to $101.60. It traded between $52.50 and $110.94 and is 8.4% below its high.
Who are Lantheus Holdings's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Lantheus Holdings's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.